Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(1R,3R)-ACPD
Description: Potent, specific NMDA agonist
Chemical Name: (1R,3R)-1-Aminocyclopentane-1,3-dicarboxylic acid
Biological Activity for (1R,3R)-ACPD
Potent NMDA receptor agonist. Active form of (±)-cis-ACPD.
Technical Data for (1R,3R)-ACPD
| M. Wt | 173.17 |
| Storage | Store at RT |
| CAS Number | 111900-33-5 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for (1R,3R)-ACPD
Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Please contact Customer Service
References for (1R,3R)-ACPD
References are publications that support the biological activity of the product.
Curry et al (1988) Synthesis, resolution, and absolute configuration of the isomers of the neuronal excitant 1-amino-1,3-cyclopentanedicarboxylic acid. J.Med.Chem. 31 403 PMID: 3351864
Mistry and Challiss (1996) Differences in agonist and antagonist activities for two indicies of metabotropic glutamate receptor-stimulated phosphoinositide turnover. Br.J.Pharmacol. 117 1735 PMID: 8732284
Sunter et al (1991) Actions of the four isomers of 1-aminocyclopentane-1,3-dicarboxylate (ACPD) in the hemisected spinal cord of the neonatal rat. Br.J.Pharmacol. 104 337P
View Related Products by Target
View Related Products by Product Action
Keywords: (1R,3R)-ACPD, (1R,3R)-ACPD supplier, NMDA, Receptors, 0288, Tocris Bioscience
Citations for (1R,3R)-ACPD
Citations are publications that use Tocris products.
Currently there are no citations for (1R,3R)-ACPD.
Reviews for (1R,3R)-ACPD
There are currently no reviews for this product. Be the first to review (1R,3R)-ACPD and earn rewards!
Have you used (1R,3R)-ACPD?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.